China
Africa
Explore chapters and articles related to this topic
Clinical Progresses in Regenerative Dentistry and Dental Tissue Engineering
Published in Vincenzo Guarino, Marco Antonio Alvarez-Pérez, Current Advances in Oral and Craniofacial Tissue Engineering, 2020
Provides a guaranteed matching donor (autologous transplant) for life. There are many advantages of autologous transplantation including no immune reaction and tissue rejection of the cells, no immunosuppressive therapy needed, and significantly reduced risk of infectious diseases.
Retroviral Gene Transfer in Autologous Bone Marrow and Stem Cell Transplantation
Published in Eric Wickstrom, Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors, 2020
Rafat Abonour, Kenneth Cornetta
Peripheral blood progenitor cells (also referred to as peripheral blood stem cells) are obtained through the process of pheresis, in which leukocytes are selectively removed from the bloodstream and the patient's red cells, platelets and plasma are returned to the circulation. This outpatient procedure lasts approximately 4 hours and can be repeated daily. Two to three phereses are usually required to obtain sufficient cells for transplantation. In autologous transplantation, peripheral blood progenitor cells have replaced autologous marrow as the source of transplantable cells in most centers. We and others have also been evaluating the use of mobilized peripheral blood progenitors in the setting of allogeneic transplantation.
Paediatric oncology
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2014
Stephen Lowis, Rachel Cox, John Moppett, Antony Ng
Salvage regimens for relapsed HL offer a significant chance of cure. Time to relapse and chemoresponsiveness at relapse are significant prognostic factors. Most patients receive autologous transplantation. OSs from relapse are in the region of 70%, though they are significantly worse for progressive disease.74,75 Allogeneic transplant with either reduced or myeloablative conditioning offers a reasonable chance of cure for high-risk cases.76
Culturing human pluripotent stem cells for regenerative medicine
Published in Expert Opinion on Biological Therapy, 2023
Hiroki Ozawa, Takuya Matsumoto, Masato Nakagawa
On the other hand, autologous transplantation is a personalized medicine approach. Cells and tissues taken from a patient at a hospital are cultured and then returned to the same patient at the same hospital. The aim is to provide the best possible treatment for the individual patient. The cell manufacturing process includes so-called upstream and downstream processes. Upstream processes include cell line establishment, cell amplification, differentiation induction. Downstream processes include cell isolation, purification, aliquoting, freezing, and packaging. Establishing these consistent process technologies is critical for ensuring the safety and efficacy of cell therapy. Cell culture is the most widely used of these processes, and improvements in cell culture technology will contribute to improved therapeutic efficacy and safety.
Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis
Published in Journal of Medical Economics, 2022
Kittima Wattanakamolkul, Yoshikazu Nakayama
When looking at allogeneic and cord blood transplantation, a significantly longer length of hospitalization and higher cost of post-HSCT hospitalization in ARTI patients as compared with non-ARTI patients were observed. On the other hand, those of autologous transplantation recipients did not. Costs of post-HSCT hospitalization in allogeneic (7,479,840.00 JPY or 95,527.97 PPPUSD) and cord blood transplantation recipients (10,488,960.00 JPY or 133,958.62 PPPUSD) were higher than those of patients with autologous transplantation (2,543,975.00 JPY or 32,490.10 PPPUSD). Similarly, a longer mean length of hospitalization (months) was observed in allogeneic and cord blood transplantation recipients (2.84 and 3.41, respectively) as compared with the autologous group (1.45) (Supplementary Table S12).
Mesenchymal stem/stromal cells as next-generation drug delivery vehicles for cancer therapeutics
Published in Expert Opinion on Drug Delivery, 2021
Yukiya Takayama, Kosuke Kusamori, Makiya Nishikawa
Both autologous and allogeneic MSCs have been assessed in clinical trials for MSC-based cancer gene therapy (Table 1). Autologous transplantation carries no risk of immune rejection. Several studies have reported that the survival time of syngeneic MSCs transplanted into mice was longer than that of allogeneic MSCs [20]. Zangi et al. reported that transplantation of allogeneic MSCs induced a memory T cell response [36]. However, some drawbacks associated with the use of autologous MSCs for transplantation tend to persist. First, the processes of an expanded culture or engineering of MSCs and validation of the final product require a prolonged period of several weeks and high cost. It is difficult to obtain sufficient BM or AD tissues in patients with low body weight and high or low age. Furthermore, MSCs isolated from patients with diabetes, rheumatoid arthritis, or systemic lupus erythematosus have shown impaired function [20]. Conversely, allogeneic MSCs are available as ‘off-the-shelf’ cell products prepared on a large scale. In addition, they can reduce the interdonor heterogeneity, as it is possible to prepare clinical doses of MSCs from one tissue source and avoid off-specification products. Recently, several cell banks of allogeneic MSCs have been established, and GMP-grade MSCs have been easily obtained [30,34,35].